 2. Have received MS therapy other than Rebif within twelve weeks prior to Screening or at any time during the trial e.g., other disease modifying drugs, Rebif New Formulation, combination therapy, immunomodulatory andor immunosuppressive agents, including but not limited to any other interferon AvonexBetaseronExtavia, glatiramer acetate Copolymer I, cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine, fingolimod FTY720, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment e.g. natalizumab, alemtuzumabCampath, anti-CD4, Intravenous immunoglobulin IVIg, cytokines or anti-cytokine therapy and telbivudine 